MA37953A1 - Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase - Google Patents
Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductaseInfo
- Publication number
- MA37953A1 MA37953A1 MA37953A MA37953A MA37953A1 MA 37953 A1 MA37953 A1 MA 37953A1 MA 37953 A MA37953 A MA 37953A MA 37953 A MA37953 A MA 37953A MA 37953 A1 MA37953 A1 MA 37953A1
- Authority
- MA
- Morocco
- Prior art keywords
- hmg
- irbesartan
- coa reductase
- inhibitor
- capsule formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une formulation de capsule composite pharmaceutique incluant les éléments suivants : 1) une unité d'irbésartan indépendante comprenant de l'irbésartan ou son sel pharmaceutiquement acceptable; et 2) une unité inhibitrice de la hmg-coa réductase indépendante comprenant un inhibiteur de la hmg-coa réductase ou son sel pharmaceutiquement acceptable, et un additif alcalin. Lesdites unités indépendantes sont séparées l'une de l'autre à l'intérieur d'une capsule. L'invention porte en outre sur son procédé de préparation. La formulation de capsule composite pharmaceutique, qui est conçue pour prévenir une interaction entre l'irbésartan et l'inhibiteur de la hmg-coa réductase, est améliorée en termes de stabilité et de taux de dissolution, et présente ainsi une meilleure biodisponibilité. En outre, la formulation garantit une observance médicamenteuse élevée en raison de sa petite taille, et peut ainsi être appliquée au traitement de l'hypertension et de l'hypercholestérolémie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120096036A KR20140030505A (ko) | 2012-08-31 | 2012-08-31 | 이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
PCT/KR2013/007841 WO2014035190A1 (fr) | 2012-08-31 | 2013-08-30 | Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase |
Publications (1)
Publication Number | Publication Date |
---|---|
MA37953A1 true MA37953A1 (fr) | 2017-01-31 |
Family
ID=50183919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37953A MA37953A1 (fr) | 2012-08-31 | 2015-03-27 | Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase |
Country Status (28)
Country | Link |
---|---|
US (1) | US20150231085A1 (fr) |
EP (1) | EP2890371A4 (fr) |
JP (1) | JP2015526509A (fr) |
KR (1) | KR20140030505A (fr) |
CN (1) | CN104602678A (fr) |
AR (1) | AR092385A1 (fr) |
AU (1) | AU2013309688A1 (fr) |
BR (1) | BR112015004091A2 (fr) |
CA (1) | CA2882738A1 (fr) |
CL (1) | CL2015000363A1 (fr) |
CO (1) | CO7350622A2 (fr) |
CR (1) | CR20150124A (fr) |
DO (1) | DOP2015000042A (fr) |
EA (1) | EA201590474A1 (fr) |
EC (1) | ECSP15010617A (fr) |
IL (1) | IL237425A0 (fr) |
IN (1) | IN2015DN01738A (fr) |
MA (1) | MA37953A1 (fr) |
MX (1) | MX2015002591A (fr) |
NI (1) | NI201500028A (fr) |
PE (1) | PE20150402A1 (fr) |
PH (1) | PH12015500395A1 (fr) |
RU (1) | RU2015111523A (fr) |
SG (1) | SG11201500580QA (fr) |
TW (1) | TW201414511A (fr) |
UY (1) | UY35000A (fr) |
WO (1) | WO2014035190A1 (fr) |
ZA (1) | ZA201502157B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101771766B1 (ko) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
EP3184103A1 (fr) * | 2015-12-21 | 2017-06-28 | Hexal AG | Composition pharmaceutique comprenant de l'atorvastatine ou un sel de celui-ci |
WO2019023198A1 (fr) * | 2017-07-25 | 2019-01-31 | Plexxikon Inc. | Formulation d'un composé modulant les kinases |
CN110237070A (zh) * | 2019-05-10 | 2019-09-17 | 辽宁大学 | 厄贝沙坦在制备降血脂药物中的应用 |
CN113476423A (zh) * | 2021-07-05 | 2021-10-08 | 海南通用三洋药业有限公司 | 一种瑞舒伐他汀钙胶囊的制备方法和瑞舒伐他汀钙胶囊 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
DE602005025755D1 (de) * | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
WO2008010008A2 (fr) * | 2006-07-17 | 2008-01-24 | Wockhardt Limited | Combinaisons cardiovasculaires faisant appel à des inhibiteurs de rennine-angiotensine |
US20110212175A1 (en) * | 2006-10-30 | 2011-09-01 | Hanall Biopharma Co., Ltd. | Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor |
EP2273985B1 (fr) * | 2008-03-28 | 2016-02-17 | Ferrer Internacional, S.A. | Capsule pour la prévention des maladies cardiovasculaires |
KR20090114332A (ko) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 약제학적 제제 |
EP2424509A4 (fr) * | 2009-04-30 | 2012-11-07 | Reddys Lab Ltd Dr | Formulations de combinaison de médicament à dose fixe |
KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
US9056134B2 (en) * | 2010-07-21 | 2015-06-16 | Nucitec S.A. De C.V. | Single daily dosage form for prevention and treatment of metabolic syndrome |
-
2012
- 2012-08-31 KR KR1020120096036A patent/KR20140030505A/ko active Search and Examination
-
2013
- 2013-08-29 AR ARP130103082A patent/AR092385A1/es unknown
- 2013-08-30 BR BR112015004091A patent/BR112015004091A2/pt not_active IP Right Cessation
- 2013-08-30 US US14/420,953 patent/US20150231085A1/en not_active Abandoned
- 2013-08-30 RU RU2015111523A patent/RU2015111523A/ru not_active Application Discontinuation
- 2013-08-30 SG SG11201500580QA patent/SG11201500580QA/en unknown
- 2013-08-30 JP JP2015529684A patent/JP2015526509A/ja active Pending
- 2013-08-30 IN IN1738DEN2015 patent/IN2015DN01738A/en unknown
- 2013-08-30 TW TW102131242A patent/TW201414511A/zh unknown
- 2013-08-30 CA CA2882738A patent/CA2882738A1/fr not_active Abandoned
- 2013-08-30 EP EP13834178.9A patent/EP2890371A4/fr not_active Withdrawn
- 2013-08-30 MX MX2015002591A patent/MX2015002591A/es unknown
- 2013-08-30 PE PE2015000255A patent/PE20150402A1/es not_active Application Discontinuation
- 2013-08-30 AU AU2013309688A patent/AU2013309688A1/en not_active Abandoned
- 2013-08-30 UY UY0001035000A patent/UY35000A/es not_active Application Discontinuation
- 2013-08-30 WO PCT/KR2013/007841 patent/WO2014035190A1/fr active Application Filing
- 2013-08-30 CN CN201380045368.3A patent/CN104602678A/zh active Pending
- 2013-08-30 EA EA201590474A patent/EA201590474A1/ru unknown
-
2015
- 2015-02-16 CL CL2015000363A patent/CL2015000363A1/es unknown
- 2015-02-24 PH PH12015500395A patent/PH12015500395A1/en unknown
- 2015-02-25 IL IL237425A patent/IL237425A0/en unknown
- 2015-02-26 DO DO2015000042A patent/DOP2015000042A/es unknown
- 2015-02-27 NI NI201500028A patent/NI201500028A/es unknown
- 2015-03-11 CR CR20150124A patent/CR20150124A/es unknown
- 2015-03-13 CO CO15058341A patent/CO7350622A2/es unknown
- 2015-03-20 EC ECIEPI201510617A patent/ECSP15010617A/es unknown
- 2015-03-27 MA MA37953A patent/MA37953A1/fr unknown
- 2015-03-30 ZA ZA2015/02157A patent/ZA201502157B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2890371A4 (fr) | 2016-04-06 |
MX2015002591A (es) | 2015-06-10 |
IN2015DN01738A (fr) | 2015-05-29 |
NI201500028A (es) | 2017-01-04 |
TW201414511A (zh) | 2014-04-16 |
CO7350622A2 (es) | 2015-08-10 |
CN104602678A (zh) | 2015-05-06 |
UY35000A (es) | 2014-03-31 |
EP2890371A1 (fr) | 2015-07-08 |
PH12015500395A1 (en) | 2015-04-27 |
CL2015000363A1 (es) | 2015-06-05 |
WO2014035190A1 (fr) | 2014-03-06 |
RU2015111523A (ru) | 2016-10-20 |
ZA201502157B (en) | 2016-10-26 |
KR20140030505A (ko) | 2014-03-12 |
ECSP15010617A (es) | 2015-12-31 |
AU2013309688A1 (en) | 2015-02-26 |
DOP2015000042A (es) | 2015-04-30 |
CA2882738A1 (fr) | 2014-03-06 |
US20150231085A1 (en) | 2015-08-20 |
CR20150124A (es) | 2015-04-24 |
AR092385A1 (es) | 2015-04-22 |
EA201590474A1 (ru) | 2015-06-30 |
PE20150402A1 (es) | 2015-04-13 |
JP2015526509A (ja) | 2015-09-10 |
BR112015004091A2 (pt) | 2017-07-04 |
IL237425A0 (en) | 2015-04-30 |
SG11201500580QA (en) | 2015-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37953A1 (fr) | Formulation de capsule composite pharmaceutique comprenant de l'irbésartan et un inhibiteur de la hmg-coa réductase | |
MA30807B1 (fr) | Compositions pharmaceutiques. | |
EP1606264A4 (fr) | Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique | |
MA37888A1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
TW200733971A (en) | CGRP peptide antagonists and conjugates | |
PH12013501341A1 (en) | Morphinan compounds | |
EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
EP1608627A4 (fr) | Antagonistes des recepteurs du cgrp spirohydantoine anilides bicycliques | |
MY178082A (en) | Solid pharmaceutical compositions and processes for their production | |
MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
MA37610B1 (fr) | Formulations de testostérone proliposomales | |
MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
MA30779B1 (fr) | Comprimes pediatriques de capecitabine | |
AU2010212580A8 (en) | Stable pharmaceutical composition for atherosclerosis | |
MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
MA43876A (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
MA33602B1 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide | |
UA107088C2 (xx) | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
MA39175A1 (fr) | Capsule comprend 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-(6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl)-1-methyl-uree, liant et desintegrant, pour le traitement des maladies proliferatives | |
MA37700B1 (fr) | N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments | |
TN2012000563A1 (fr) | Nouvelle association entre le 4(3-(cis-hexahydrocyclopenta(c)pyrrol-2(1-h)-yl)propoxy)benzamide et un antagoniste des recepteurs nmda et les compositions pharmaceutiques qui la contiennent. | |
ATE482195T1 (de) | Benzoäfüisoindole als antagonisten des ep4- rezeptors | |
EA201170583A1 (ru) | Новая композиция для лечения эссенциальной тромбоцитемии | |
IN2015DN02296A (fr) |